Daniel Gonzalez

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: October 11, 2020

Lactobacillus stress protein GroEL prevents colonic inflammation.

Journal: Journal of gastroenterology

Published: June 20, 2020

The Drosophila odorant-binding protein 28a is involved in the detection of the floral odour ß-ionone.

Journal: Cellular and molecular life sciences : CMLS

Published: April 09, 2019

Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].

Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].

Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.

Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.

Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer.

Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer.

Deep Learning on Histologic Slides Accurately Predicts Consensus Molecular Subtypes and Spatial Heterogeneity in Colon Cancer.

Deep Learning on Histologic Slides Accurately Predicts Consensus Molecular Subtypes and Spatial Heterogeneity in Colon Cancer.

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.

FedECA: federated external control arms for causal inference with time-to-event data in distributed settings.

FedECA: federated external control arms for causal inference with time-to-event data in distributed settings.

Faecalibacteriumprausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial.

Faecalibacteriumprausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial.

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

Lactobacillus stress protein GroEL prevents colonic inflammation.

Lactobacillus stress protein GroEL prevents colonic inflammation.

The Drosophila odorant-binding protein 28a is involved in the detection of the floral odour ß-ionone.

The Drosophila odorant-binding protein 28a is involved in the detection of the floral odour ß-ionone.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.